Opioid Cough Medicine Use for Children Drops to Near-Zero in U.S.

The analysis, conducted by Motive Medical Intelligence, examined data from October 2022 through September 2024. It reveals that the reliance on codeine and hydrocodone—ingredients historically found in common pediatric cough syrups—has largely vanished from clinical practice. While states like Nevada and Vermont reported zero prescriptions during the study period, even regions with the highest usage, such as Wyoming, showed rates statistically indistinguishable from the national average.

A Shift in Clinical Standards

For decades, physicians frequently prescribed these opioids for stubborn coughs, often at the request of parents seeking relief for their children. This occurred despite a lack of clinical evidence supporting their efficacy and mounting data regarding serious risks, including respiratory depression and death. The shift began in earnest following warnings from the World Health Organization and the FDA, compounded by a 2016 American Academy of Pediatrics report that highlighted dozens of codeine-related fatalities. Dr. Rich Klasco, Chief Medical Officer at Motive, noted that these findings demonstrate how deeply entrenched habits can change when the medical community aligns behind clear, evidence-based standards.